Quinazolines as potassium ion channel inhibitors

US10676460B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• James A. Johnson · Lawrenceville, US
• John Lloyd · Yardley, US
• Heather Finlay · Skillman, US
• James Neels · Newtown, US
• Naveen Kumar Dhondi · Secunderabad, IN
• Prashantha Gunaga · Savanuru, IN
• Abhisek Banerjee · Narayanpur, IN
• Ashokkumar Adisechan · Navi Mumbai, IN

Key dates

• Filing date: Jan 9, 2019
• Grant date: Jun 9, 2020
• Expiry date: Jan 9, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D513/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A compound of formula I wherein A, X, Y, Z, R1 and R24 are described herein. The compounds are useful as inhibitors of potassium channel function and in the treatment and prevention of arrhythmia, IKur-associated disorders, and other disorders mediated by ion channel function.